Tags: Life Sciences
Belgium aims for hospitals to increase their biosimilars uptake
Despite many initiatives by the (former) Minister of Health, the uptake of biosimilars in Belgium has remained rather low. In this blog, we summarise the new rules, which apply since 2 October 2023.
The Belgian Competition Authority publishes a specific analytical framework for hospital concentrations
This article is an updated version of our previous article on the uncertainty regarding hospital merger control, focusing on the BCA’s decision of 28 June 2023.
WEBINAR VIDEO | Navigating Mergers and Acquisitions in Life Sciences: Insights for Success and Pitfalls to avoid
During this webinar, the experts from our assembled transactions team, Richard Liu, Mieke D’hanis and Pauline Geentjens, provide valuable insights, inform you of common pitfalls and let you in on a number of tips and tricks during an Mergers and Acquisitions process.
New product liability regime on the way
The European Commission published a draft proposal for a revised Product Liability Directive (the “PLD Proposal”) on 28 September 2022, which aims to bring the European Union’s product liability regime ‘up to speed’ with the digital age, circular economy business models and global value chains.
Navigating Mergers and Acquisitions in Life Sciences: Insights for Success and Pitfalls to avoid
The experts from our assembled transactions team will provide valuable insights, inform you of common pitfalls and let you in on a number of tips and tricks during an M&A process.
Kirian Claeyé promoted to partner at ALTIUS
ALTIUS is delighted to announce that Kirian Claeyé has been promoted to partner as per September 2023. Congratulations Kirian!
The Belgian Competition Authority has declared itself competent to examine mergers and acquisitions between hospitals under its merger control regime, following the Act of 29 March 2021
A lot of uncertainty has existed about the requirement for hospitals to notify M&A transactions to the Belgian Competition Authority (“BCA”). On 28 June 2023, the BCA decided to partially lift the stand-still obligation regarding a concentration between two hospitals, and it further clarified the applicable rules in a follow-up Communication of 14 July 2023.
WEBINAR VIDEO | The New EU Deforestation Regulation: Stay Compliant, Succeed Sustainably
In this Life Sciences session, the experts from our agri-food law team Philippe de Jong and Bart Junior Bollen provided valuable insights into the Regulation’s implications and equiped businesses with the necessary knowledge to ensure compliance in this evolving landscape.
Belgian Medicines Agency announces stricter monitoring of negative formulations on medicines packaging
On 17 May 2023, the Belgian Medicines Agency (FAMHP) announced that marketing authorisation holders (MAHs) have three years to comply with the prohibition of “negative formulations” on the packaging of medicinal products for human use.
The New EU Deforestation Regulation: Stay Compliant, Succeed Sustainably
You are warmly invited to our upcoming webinar on the topic of the recently published EU Deforestation Regulation, presented from a legal perspective.
CJEU interprets the concept of a global MA strictly
On 16 March 2023, in Joined Cases C‑438/21 P to C‑440/21 P, the Court of Justice of the European Union (CJEU) interpreted the concept of a ‘global marketing authorisation’. It held that Article 6(1) of Directive 2001/83 (the Community Code) sets out exhaustively the line extensions for which the marketing authorisations (MAs) will fall under the same global MA as the initial MA.
Agri-Food Law Seminar
We are excited to announce that our annual Agri-food Law Seminar will take place on 9 June 2023!